TLR7 and glioblastoma: It encapsulated Fe3O4 NPs and TLR7 agonist imiquimod (R837), which could synergistically repolarize TAMs from M2 to antitumor M1 phenotype.1086 Resiquimod, also known as R848, is a TLR7/8 agonist shown to enhance cancer immunotherapy by promoting the transformation of M2 macrophages into M1.1087,1088 In vitro studies have shown that cathepsin B (CTSB)-responsive programmed brain-targeted delivery system (D&R-HM-MCA) could go through the BBB of glioblastoma (GBM) with high endocytosis efficiency and promote the repolarization of M2 macrophages into M1 type by the delivery of resiquimod.1089